1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA Staff Slams Agency Hiring Policies In Report Ahead Of Public Meeting

 
• By Michael Cipriano

Agency to discuss results of report, as well as pending 2018 pilot project designed to modernize its hiring practices.

FDA entrance sign 2016

The level of frustration that mangers at the US FDA have with the agency’s hiring practices probably can’t be overstated. One individual in the agency’s executive leadership has "no idea" how to evaluate a center's hiring performance, while a hiring manager noted that there is "a profound disconnect of mission" in recruiting and retaining talented staff.

These were just a few of the rather scathing assessments of FDA's hiring process in a Nov. 15

FDA commissioned the report to diagnose the root causes of challenges in the hiring process, and to outline a path forward to meet its staffing commitments in the user fee reauthorizations. (Also see "FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds" - Pink Sheet, 21 July, 2016

More from US FDA

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

More from Agency Leadership

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.

HHS Secretary Kennedy Says Trump Will Make Final Decision On Mifepristone Policy

 
• By Derrick Gingery

With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.